🔎 Trials Near Me

Почетна › Немалоклетни карцином плућа › Kentaki › Lexington

Kliničke studije za Немалоклетни карцином плућа u gradu Lexington, KY

24 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u gradu Lexington i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Тражи се учесникФаза 3
  • Baptist Health Lexington, Lexington
  • Baptist Health Hamburg, Lexington
  • University of Kentucky/Markey Cancer Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Тражи се учесникФаза 3
  • Baptist Health Lexington, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06561386

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Тражи се учесникФаза 3
  • University of Kentucky/Markey Cancer Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07388524

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Тражи се учесникФаза 3
  • University of Kentucky Chandler Medical Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07361497

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Тражи се учесникФаза 3
  • Baptist Health Lexington, Lexington
  • Baptist Health Hamburg, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06890598

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Тражи се учесникОпсервациона студија
  • Saint Joseph Hospital East, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Тражи се учесникФаза 3
  • University of Kentucky Chandler Medical Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Тражи се учесникФаза 1/2
  • University of Kentucky HealthCare (UK HealthCare), Lexington
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07397338

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Тражи се учесникФаза 2/3
  • Baptist Health Lexington, Lexington
  • University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06712316

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Тражи се учесникФаза 2/3
  • Lexington Medical Cancer Center Hematology/Oncology, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT04613596

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Тражи се учесникФаза 3
  • Research Site, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06692738

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Тражи се учесникФаза 2
  • Baptist Health Lexington, Lexington
  • Baptist Health Hamburg, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07680764

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Тражи се учесникФаза 2
  • University of Kentucky ( Site 0019), Lexington
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06731907

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

Тражи се учесникФаза 2
  • University of Kentucky Markey Cancer Center, Lexington
Узраст од 18 до 99 · Оба пола · Ажурирано 14. 10. 2026. · NCT07770100

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Тражи се учесникФаза 2
  • University of Kentucky/Markey Cancer Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Тражи се учесникФаза 2
  • University of Kentucky/Markey Cancer Center, Lexington
18 Minutes · Оба пола · Ажурирано 9. 10. 2026. · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Тражи се учесникФаза 2/3
  • Markey Cancer Center at Lexington Clinic, Lexington
  • University of Kentucky/Markey Cancer Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06616584

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Тражи се учесникФаза 3
  • Research Site, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06868277

Pan-tumor MRD Study

Тражи се учесникОпсервациона студија
  • Baptist Health Lexington, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT06605404

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Тражи се учесникФаза 3
  • Clinical Study Site, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT06767514

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Тражи се учесникФаза 1/2
  • Markey Cancer Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT04486833

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Тражи се учесникФаза 1
  • University of Kentucky Chandler Medical Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT05142189

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Тражи се учесникФаза 1
  • UK Markey Cancer Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 11. 6. 2026. · NCT05283330

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Тражи се учесникФаза 2
  • University of Kentucky/Markey Cancer Center, Lexington
Узраст 18 и старији · Оба пола · Ажурирано 3. 6. 2026. · NCT05642572

Studije za Немалоклетни карцином плућа u drugim gradovima

Ostale studije u gradu Lexington

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.